{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=25&state=California", "query": { "state": "California", "city": "Fullerton", "page": 25 }, "page_size": 10 }, "pagination": { "page": 25, "page_size": 10, "total_count": 1115, "total_pages": 112, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=26&state=California&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Fullerton&page=24&state=California&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-31T22:18:20.509Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06698042", "title": "A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer", "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab (+) Berahyaluronidase alfa", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2024-11-21", "completion_date": "2027-04-17", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-10-31T22:18:20.509Z", "location_count": 4, "location_summary": "Fullerton, California • Peoria, Illinois • The Bronx, New York + 1 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Peoria", "state": "Illinois" }, { "city": "The Bronx", "state": "New York" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06698042" }, { "nct_id": "NCT05103683", "title": "First in Human Study of TORL-1-23 in Participants With Advanced Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Ovarian Cancer", "Endometrial Cancer", "NSCLC" ], "interventions": [ { "name": "TORL-1-23", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TORL Biotherapeutics, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2021-11-17", "completion_date": "2026-11-15", "has_results": false, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-31T22:18:20.509Z", "location_count": 9, "location_summary": "Fullerton, California • Los Angeles, California • Lexington, Kentucky + 6 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05103683" }, { "nct_id": "NCT05637801", "title": "A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (HOPE Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Alzheimer Disease", "Alzheimer Disease 1", "Alzheimer Disease 2", "Alzheimer Disease 3", "Alzheimer Disease, Early Onset", "Alzheimer Disease, Late Onset", "Alzheimer Disease 9", "Alzheimer Disease 4", "Alzheimer Disease 7", "Alzheimer Disease 17", "Alzheimer's Dementia Late Onset", "Alzheimer Disease 5", "Alzheimer Disease 6", "Alzheimer Disease 8", "Alzheimer Disease 10", "Alzheimer Disease 11", "Alzheimer Disease 12", "Alzheimer Disease 13", "Alzheimer Disease 14", "Alzheimer Disease 15", "Alzheimer Disease 16", "Alzheimer Disease 18", "Alzheimer Disease 19", "Dementia", "Dementia Alzheimers", "Dementia, Mild", "Dementia of Alzheimer Type", "Dementia Moderate", "Dementia Senile", "Mild Cognitive Impairment", "Mild Dementia", "MCI", "Cognitive Impairment", "Cognitive Decline", "Cognitive Impairment, Mild" ], "interventions": [ { "name": "Spectris™ AD - Active", "type": "DEVICE" }, { "name": "Spectris™ AD - Sham", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Cognito Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "50 Years to 90 Years" }, "enrollment_count": 673, "start_date": "2022-12-13", "completion_date": "2026-08-17", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-31T22:18:20.509Z", "location_count": 68, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Sun City, Arizona + 62 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05637801" }, { "nct_id": "NCT00609622", "title": "Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "sunitinib", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 191, "start_date": "2008-04", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2012-10-11", "last_synced_at": "2026-10-31T22:18:20.509Z", "location_count": 81, "location_summary": "Fairhope, Alabama • Mobile, Alabama • Chandler, Arizona + 65 more", "locations": [ { "city": "Fairhope", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Bentonville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00609622" }, { "nct_id": "NCT03419234", "title": "Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration Levels of Testosterone", "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Carcinoma in the Soft Tissue", "Prostate Carcinoma Metastatic in the Bone", "Stage IV Prostate Adenocarcinoma AJCC v7" ], "interventions": [ { "name": "Abiraterone Acetate", "type": "DRUG" }, { "name": "Androgen deprivation therapy", "type": "DRUG" }, { "name": "Cabazitaxel", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ECOG-ACRIN Cancer Research Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 223, "start_date": "2018-04-26", "completion_date": "2028-04-01", "has_results": true, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-31T22:18:20.509Z", "location_count": 665, "location_summary": "Fairbanks, Alaska • Goodyear, Arizona • Kingman, Arizona + 437 more", "locations": [ { "city": "Fairbanks", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Hot Springs", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03419234" }, { "nct_id": "NCT05097287", "title": "Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Dupilumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1339, "start_date": "2021-12-16", "completion_date": "2029-06-08", "has_results": false, "last_update_posted_date": "2026-04-16", "last_synced_at": "2026-10-31T22:18:20.509Z", "location_count": 75, "location_summary": "Cullman, Alabama • Sheffield, Alabama • Chandler, Arizona + 66 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "Sheffield", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT05097287" }, { "nct_id": "NCT07630649", "title": "Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD" ], "interventions": [ { "name": "Ixo-vec", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Adverum Biotechnologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 15, "start_date": "2026-06-02", "completion_date": "2031-06", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-31T22:18:20.509Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Bakersfield, California • Fullerton, California + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07630649" }, { "nct_id": "NCT01806064", "title": "Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Renal Cell Carcinoma" ], "interventions": [ { "name": "TRC105 and Axitinib", "type": "DRUG" }, { "name": "Axitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tracon Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 173, "start_date": "2013-03-08", "completion_date": "2019-06-12", "has_results": true, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-10-31T22:18:20.509Z", "location_count": 28, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01806064" }, { "nct_id": "NCT01120249", "title": "S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Kidney Cancer" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 1545, "start_date": "2011-04-01", "completion_date": "2025-09-01", "has_results": true, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-10-31T22:18:20.509Z", "location_count": 1002, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Fairbanks, Alaska + 609 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Fairbanks", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01120249" }, { "nct_id": "NCT02155660", "title": "Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Moderate to Very Severe Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Benralizumab Arm A", "type": "DRUG" }, { "name": "Benralizumab Arm B", "type": "DRUG" }, { "name": "Benralizumab Arm C", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "40 Years to 85 Years" }, "enrollment_count": 2255, "start_date": "2014-06-25", "completion_date": "2018-04-09", "has_results": true, "last_update_posted_date": "2019-06-26", "last_synced_at": "2026-10-31T22:18:20.509Z", "location_count": 151, "location_summary": "Birmingham, Alabama • Gulf Shores, Alabama • Montgomery, Alabama + 127 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gulf Shores", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Flagstaff", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02155660" } ] }